Sex disparities in cystic fibrosis in the era of highly effective modulator treatment

被引：0
作者：
Emma McNally [1 ]
Michelle Casey [2 ]
机构：
[1] Department of Respiratory Medicine, Beaumont Hospital, Dublin
[2] Cystic Fibrosis Unit, Beaumont Hospital, Dublin
[3] Department of Medicine, Royal College of Surgeons in Ireland, Dublin
来源：
BMC Pulmonary Medicine | / 25卷 / 1期
关键词：
Cystic fibrosis; Disparity; Hormone; Modulator; Sex;
D O I：
10.1186/s12890-025-03621-0
中图分类号：
学科分类号：
摘要：
Cystic fibrosis (CF) is a genetic disorder characterized by progressive lung disease and extra-pulmonary manifestations with notable sex disparities in disease outcomes. In this review we summarize the underlying mechanisms driving this sex disparity, with a particular focus on the role of sex hormones on CF lung disease pathophysiology. We explore how the introduction of highly effective modulator therapies (HEMT) may impact sex differences in outcomes and assess whether they have the potential to close the sex gap. While treatment with HEMT has led to better outcomes in the CF population as a whole, females with CF continue to experience worse pulmonary morbidity than males. There is a need for continued research in this area, particularly into the influence and therapeutic potential of sex hormones. © The Author(s) 2025.
引用
收藏
相关论文
共 101 条
[1]  
Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Et al., Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Science, 245, 4922, pp. 1066-1073, (1989)
[2]  
Keogh R.H., Szczesniak R., Taylor-Robinson D., Bilton D., Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data, J Cyst Fibros, 17, 2, pp. 218-227, (2018)
[3]  
Kerem E., Reisman J., Corey M., Canny G.J., Levison H., Prediction of mortality in patients with cystic fibrosis, N Engl J Med, 326, 18, pp. 1187-1191, (1992)
[4]  
Rosenfeld M., Davis R., FitzSimmons S., Pepe M., Ramsey B., Gender gap in cystic fibrosis mortality, Am J Epidemiol, 145, 9, pp. 794-803, (1997)
[5]  
Trust C.F., UK Cystic Fibrosis Registry 2022 Annual Data Report, (2022)
[6]  
Besier T., Schmitz T.G., Goldbeck L., Life satisfaction of adolescents and adults with cystic fibrosis: impact of partnership and gender, J Cyst Fibros, 8, 2, pp. 104-109, (2009)
[7]  
Patterson J.M., Wall M., Berge J., Milla C., Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire, J Cyst Fibros, 7, 2, pp. 154-164, (2008)
[8]  
Patterson J.M., Wall M., Berge J., Milla C., Associations of psychosocial factors with health outcomes among youth with cystic fibrosis, Pediatr Pulmonol, 44, 1, pp. 46-53, (2009)
[9]  
Putman M.S., Norris A.W., Hull R.L., Rickels M.R., Sussel L., Blackman S.M., Et al., Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes, Diabetes Care, 46, 6, pp. 1112-1123, (2023)
[10]  
Hart N.J., Aramandla R., Poffenberger G., Fayolle C., Thames A.H., Bautista A., Spigelman A.F., Babon J.A.B., DeNicola M.E., Dadi P.K., Bush W.S., Balamurugan A.N., Brissova M., Dai C., Prasad N., Bottino R., Jacobson D.A., Drumm M.L., Kent S.C., MacDonald P.E., Powers A.C., Cystic fibrosis-related diabetes is caused by islet loss and inflammation, JCI Insight, 3, 8, (2018)
12345678910